In a groundbreaking real-world study, Eli Lilly's Mounjaro (tirzepatide) demonstrated superior weight loss compared to Novo Nordisk's Ozempic (semaglutide), both of which are popular drugs for treating type 2 diabetes and obesity. This study, published in JAMA Internal Medicine, marks...